Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P29350
UPID:
PTN6_HUMAN
Alternative names:
Hematopoietic cell protein-tyrosine phosphatase; Protein-tyrosine phosphatase 1C; Protein-tyrosine phosphatase SHP-1; SH-PTP1
Alternative UPACC:
P29350; A8K306; G3V0F8; Q969V8; Q9UK67
Background:
Tyrosine-protein phosphatase non-receptor type 6, also known as Hematopoietic cell protein-tyrosine phosphatase, Protein-tyrosine phosphatase 1C, Protein-tyrosine phosphatase SHP-1, and SH-PTP1, plays a pivotal role in modulating signaling pathways initiated by tyrosine phosphorylated cell surface receptors such as KIT and EGFR. Its interaction with cellular components through SH2 regions and collaboration with MTUS1 to induce UBE2V2 expression upon angiotensin II stimulation underscores its significance in cellular signaling and hematopoiesis.
Therapeutic significance:
Understanding the role of Tyrosine-protein phosphatase non-receptor type 6 could open doors to potential therapeutic strategies.